Publication:
Influence of human telomerase reverse transcriptase mutation on the aggressiveness and recurrence in meningiomas

dc.contributor.coauthorSahin, Balkan
dc.contributor.coauthorKatar, Salim
dc.contributor.coauthorSahin, Saime A.
dc.contributor.coauthorCevik, Serdar
dc.contributor.coauthorEvran, Sevket
dc.contributor.coauthorTanik, Canan
dc.contributor.coauthorAdilay, Huseyin U.
dc.contributor.coauthorYilmaz, Adem
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorBaran, Oğuz
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:34:48Z
dc.date.issued2021
dc.description.abstractBackground: Over 200 human telomerase reverse transcriptase (hTERT) polymorphism combinations have been implicated in the development of cancer. This study aimed to evaluate hTERT mutations in meningioma tissue and its association with meningioma. Material and Methods: A total of 90 patients who underwent surgery between 2006 and 2015 and were histopathologically diagnosed with meningioma (WHO 2016) were included. Results: Among the 90 participants included herein, 50 (55.5%) and 40 (44.5%) were female and male, respectively, with an average age of 56.2 +/- 14 years. Mean Ki-67 values were 10.56% (SD 12.41, range 0-60), while the mean follow-up duration was 39.1 months (SD 26.3). Low- and high-grade patients had a mean Ki-67 score of 4.31% (SD 3.58, range 0-16) and 19.92% (SD 14.91, range 2-60) (p = 0.0001). Our results showed a moderate positive correlation between Ki-67 score and the presence of hTERT mutation (Pearson correlation lest, r = 0.5161; p = 0.0001). Patients with an hTERT mutation > 30% had significantly higher risk for reoperation than those with lower levels of mutation (p = 0.016, chi square test). None of the patients requiring reoperation had an hTERT mutation < 10%. Moreover, high-grade patients had a 7.2 times higher risk of reoperation than those with an hTERT mutation > 30%. Conclusion: The presence of hTERT mutation, in addition to high Ki-67, indicated a more aggressive meningioma disease course and potentially increased risk of recurrence.
dc.description.indexedbyWOS
dc.description.indexedbyPubMed
dc.description.issue5
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume13
dc.identifier.doi10.7759/cureus.15342
dc.identifier.eissn2168-8184
dc.identifier.quartileN/A
dc.identifier.urihttps://doi.org/10.7759/cureus.15342
dc.identifier.urihttps://hdl.handle.net/20.500.14288/12414
dc.identifier.wos657837600001
dc.keywordsMeningioma
dc.keywordsTelomerase reverse transcriptase
dc.keywordsMalignant progression
dc.keywordsRecurrent meningioma
dc.keywordsTert promoter tert promoter mutations
dc.keywordsExpression
dc.keywordsProtein
dc.language.isoeng
dc.publisherCureus Journal of Medical Science
dc.relation.ispartofCureus Journal of Medical Science
dc.subjectMedicine
dc.subjectGeneral
dc.subjectInternal
dc.titleInfluence of human telomerase reverse transcriptase mutation on the aggressiveness and recurrence in meningiomas
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorBaran, Oğuz
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files